Climara patch
Climara is a once-weekly transdermal estradiol patch that delivers bioidentical estradiol through the skin to treat menopause symptoms.
How it works
Climara is a once-weekly estradiol patch — the extended wear time compared to twice-weekly patches is the primary practical distinction. Like all transdermal estradiol, it bypasses liver first-pass metabolism, which is associated with a more favorable cardiovascular and clotting risk profile compared to oral estrogen. The once-weekly schedule suits people who find twice-weekly changes difficult to maintain consistently; fewer change days mean fewer opportunities for a missed or late change to disrupt estradiol levels.
For people with a uterus, Climara must be used with a progestogen to prevent endometrial hyperplasia — progesterone or a progestin is added separately. Skin reactions at the application site are the most common tolerability issue; rotating sites weekly reduces cumulative irritation. Climara is available in multiple dose strengths, and finding the lowest effective dose is the standard treatment goal.
How to track Climara patch
- Hot flash frequency and severity — the primary indicator of therapeutic adequacy.
- Weekly change day adherence — with once-weekly patches, a late change is more likely than with twice-weekly dosing; logging change days reveals whether any symptom flares correlate with delayed changes.
- Skin reactions at the application site — redness, itching, or adhesion problems should be logged with site location.
- Night sweats and sleep quality as secondary response indicators.
- Side effects suggesting dose overshoot: breast tenderness, bloating, headaches.
- Pick the same day of the week for changes and log it — late weekly patches cause steeper end-of-cycle estradiol drops than late twice-weekly patches, since there are fewer mid-cycle corrections.
- Rotate among at least three to four sites (lower abdomen, buttocks, lower back) and log site with each change — repeated use of the same site accelerates skin irritation.
- Track symptom levels in the days just before your weekly change; if you consistently see hot flash increases on days five to seven, that end-of-cycle drop is meaningful data for a dose conversation.
- Log breast tenderness and bloating as dose-overshoot indicators — these are more actionable than other side effects for guiding dose adjustments.
- At the four- and eight-week marks, compare weekly hot flash averages to your pre-treatment baseline — that is the standard evaluation interval for transdermal dose optimization.
Questions to ask your physician
- My log shows hot flash frequency rising on days [X-Y] of my weekly cycle, just before my change day. Does that suggest an end-of-cycle drop that warrants a dose or timing adjustment?
- I've been tracking skin irritation at [sites] consistently — here is the pattern. Should I try different sites or a different patch brand?
- My pre-treatment baseline was [X] hot flashes per day. At [N] weeks on Climara, my current weekly average is [Y]. Is that trajectory typical for this dose?
- My adherence log shows I delayed my patch change by [X days] on [dates]. Could those delays account for the symptom spikes I logged on [dates]?